| Bevacizumab plus irinotecan in recurrent glioblastoma multiforme JJ Vredenburgh, A Desjardins, JE Herndon, J Marcello, DA Reardon, ... Journal of clinical oncology 25 (30), 4722-4729, 2007 | 1707 | 2007 |
| Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial DA Reardon, AA Brandes, A Omuro, P Mulholland, M Lim, A Wick, ... JAMA oncology 6 (7), 1003-1010, 2020 | 1039 | 2020 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The lancet oncology 18 (10), 1373-1385, 2017 | 974 | 2017 |
| Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma JH Sampson, AB Heimberger, GE Archer, KD Aldape, AH Friedman, ... Journal of clinical oncology 28 (31), 4722-4729, 2010 | 903 | 2010 |
| Phase II trial of gefitinib in recurrent glioblastoma JN Rich, DA Reardon, T Peery, JM Dowell, JA Quinn, KL Penne, ... Journal of Clinical Oncology 22 (1), 133-142, 2004 | 873 | 2004 |
| Recurrent glioblastoma treated with recombinant poliovirus A Desjardins, M Gromeier, JE Herndon, N Beaubier, DP Bolognesi, ... New England Journal of Medicine 379 (2), 150-161, 2018 | 737 | 2018 |
| Challenges to curing primary brain tumours K Aldape, KM Brindle, L Chesler, R Chopra, A Gajjar, MR Gilbert, ... Nature reviews Clinical oncology 16 (8), 509-520, 2019 | 709 | 2019 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ... The Lancet Oncology 16 (15), e534-e542, 2015 | 697 | 2015 |
| Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma JH Sampson, JH Carter, AH Friedman, HF Seigler Journal of neurosurgery 88 (1), 11-20, 1998 | 668 | 1998 |
| Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma PE Fecci, DA Mitchell, JF Whitesides, W Xie, AH Friedman, GE Archer, ... Cancer research 66 (6), 3294-3302, 2006 | 651 | 2006 |
| Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients DA Mitchell, KA Batich, MD Gunn, MN Huang, L Sanchez-Perez, SK Nair, ... Nature 519 (7543), 366-369, 2015 | 564 | 2015 |
| Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors P Chongsathidkiet, C Jackson, S Koyama, F Loebel, X Cui, SH Farber, ... Nature medicine 24 (9), 1459-1468, 2018 | 526 | 2018 |
| Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma S Kunwar, S Chang, M Westphal, M Vogelbaum, J Sampson, G Barnett, ... Neuro-oncology 12 (8), 871-881, 2010 | 518 | 2010 |
| Proteomic and immunologic analyses of brain tumor exosomes MW Graner, O Alzate, AM Dechkovskaia, JD Keene, JH Sampson, ... The FASEB Journal 23 (5), 1541, 2009 | 512 | 2009 |
| Brain immunology and immunotherapy in brain tumours JH Sampson, MD Gunn, PE Fecci, DM Ashley Nature Reviews Cancer 20 (1), 12-25, 2020 | 496 | 2020 |
| Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma DA Mitchell, W Xie, R Schmittling, C Learn, A Friedman, RE McLendon, ... Neuro-oncology 10 (1), 10-18, 2008 | 451 | 2008 |
| Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 A Omuro, G Vlahovic, M Lim, S Sahebjam, J Baehring, T Cloughesy, ... Neuro-oncology 20 (5), 674-686, 2018 | 448 | 2018 |
| A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study J Schuster, RK Lai, LD Recht, DA Reardon, NA Paleologos, MD Groves, ... Neuro-oncology 17 (6), 854-861, 2015 | 414 | 2015 |
| Prospects of immune checkpoint modulators in the treatment of glioblastoma M Preusser, M Lim, DA Hafler, DA Reardon, JH Sampson Nature Reviews Neurology 11 (9), 504-514, 2015 | 407 | 2015 |
| Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function PE Fecci, H Ochiai, DA Mitchell, PM Grossi, AE Sweeney, GE Archer, ... Clinical cancer research 13 (7), 2158-2167, 2007 | 386 | 2007 |
Patrick C. Gedeon, M.D., Ph.D.Mass General Brigham and Dana-Farber Cancer InstituteVerified email at mgb.org
